Join the 'Corticotropin' group to help and get support from people like you.
Posted 18 Oct 2010 by Drugs.com
ANAHEIM, Calif., Oct. 15 /PRNewswire-FirstCall/ – Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced the U.S. Food and Drug Administration (FDA) has approved Questcor's supplemental new drug application (sNDA) for H.P. Acthar Gel (repository corticotropin injection) in the treatment of infantile spasms (IS), an ultra-rare orphan disorder affecting approximately 2,000 American children annually. IS is a devastating and potentially life-threatening form of epilepsy seen in infancy and early childhood. "The approval of Acthar for infantile spasms is an example of Questcor's clear focus on helping patients with serious, difficult-to-treat medical conditions," said Don M. Bailey, president and CEO of Questcor. "Today's approval is an important milestone for babies afflicted with IS, as well as the doctors, nurses and parents who care for them. The FDA approval of Acthar for IS ... Read more
Related support groups: Corticotropin
Ask a Question
Related Condition Support Groups
Ankylosing Spondylitis, Allergies, Chorioditis, Juvenile Rheumatoid Arthritis, Chorioretinitis, Multiple Sclerosis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Polymyositis / Dermatomyositis, view more... Eye Conditions, West Syndrome, Sarcoidosis, Serum Sickness, Stevens-Johnson Syndrome, Uveitis, Ulcerative Colitis, Psoriasis, Iritis, Iridocyclitis, Inflammatory Bowel Disease, Keratitis, Erythema Mulitforme, Focal Segmental Glomerulosclerosis, Optic Neuritis, Psoriatic Arthritis